We have recently shown that comprehensive liquid biopsy analysis including the analysis of PIK3CA mutations in CTCs and ctDNA is a very informative tool for the early detection of minimal residual disease in breast cancer (52). This evidence concerns the gene PIK3CA and breast cancer.